Watch CBS News

Valeant psoriasis treatment rejected by FDA

Federal health regulators have declined to approve a lotion developed by Valeant Pharmaceuticals to treat plaque psoriasis, a common skin condition.

The Food and Drug Administration did not point to anything lacking in the safety or efficacy of the treatment, called Duobrii, Valent said in a statement on Monday. The agency's letter "only noted questions regarding pharmacokinetic data," Joseph Papa, Valeant's chairman and CEO, said.

Valeant shares fell nearly 7 percent in early morning trade after news of the FDA denial came out.

The drugmaker has asked for a meeting with the FDA to settle the matter, which Valeant hopes to resolve quickly, the company said.

Plaque psoriasis causes dry, itchy patches on the skin, with symptoms including a rash. About 7.5 million Americans suffer from psoriasis, according to the American Academy of Dermatology.

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.